Haemoadsorption During Heart Transplantation

Recruiting N/A Interventional Study
Heart Transplantation
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
40 (estimated)
Sponsor
Medical University of Vienna · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
To investigate whether the use of haemoadsorption (HA) on cardiopulmonary bypass during heart transplantation (HTX) has an effect on circulating cytokine levels for the first 120 hours after HTX and induces a decreased inflammatory response, increased anti-inflammatory response or immunosuppressive response. Additionally, the influence of HA on primary graft dysfunction, postoperative cerebral dys…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Adult patients undergoing heart transplantation Exclusion Criteria: * Declined informed consent * Age \< 18 years# * Receiving antileukocyte drugs * Receiving TNF-α Blockers, immunosuppressive drugs (e.g. tocilizumab) * DCD * Ex-vivo perfusion
Contacts

Martin H. Bernardi, MD, PhD

0043140400

martin.bernardi@meduniwien.ac.at

CONTACT